DLC1 isoform 1 may represent a new target for SMA gene therapy

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Oct 12 / Springer Healthcare

DLC1 isoform 1 may represent a new target for SMA gene therapy

Neuroscience Spinal Muscular Atrophy WMS-2022

Description

Martin Cheung describes a genetic study showing that loss or reduced expression of DLC1 isoform 1 may contribute to motor neuron defects in spinal muscular atrophy, and discusses the potential of this gene as a therapeutic target.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.